Effect of captopril on renal function in patients with congestive heart failure.

Angiotensin converting enzyme inhibitors can improve haemodynamics in patients with congestive heart failure and may enhance sodium excretion in hypertensive patients. In a metabolic unit we assessed the effects of one of these agents on renal function in nine patients with stable New York Heart Association functional class 3 or 4 congestive heart failure. Single blinded, the patients received placebo for three days, 25 to 100 mg of captopril three times a day for three days, and three more days of placebo. Mean blood pressure decreased during captopril, with little change in heart rate or respiration. Serum urea was slightly higher during captopril administration. The mean change in creatinine clearance during captopril was insignificant, but it decreased more than 25% in three of nine patients. Decreases in creatinine clearance correlated with lower blood pressure during captopril and were most obvious in patients with high baseline plasma renin activity. Urine output and both sodium and potassium excretion decreased during captopril. Thus captopril failed to improve natriuresis in patients with congestive heart failure and close monitoring of kidney function is necessary when using this agent in patients with congestive heart failure, particularly when blood pressure falls to lower levels.

[1]  E. Espiner,et al.  HAEMODYNAMIC, HORMONAL, AND ELECTROLYTE RESPONSES TO CAPTOPRIL IN RESISTANT HEART FAILURE , 1981, The Lancet.

[2]  D. Sharpe,et al.  LOW-DOSE CAPTOPRIL IN CHRONIC HEART FAILURE: ACUTE HAEMODYNAMIC EFFECTS AND LONG-TERM TREATMENT , 1980, The Lancet.

[3]  J. Brown,et al.  Captopril in clinical hypertension. Changes in components of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin II during converting enzyme inhibition. , 1980, British heart journal.

[4]  J. Laragh,et al.  Proteinuria during long-term captopril therapy. , 1980, JAMA.

[5]  N. Hollenberg,et al.  Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. , 1980, The New England journal of medicine.

[6]  J. Weening,et al.  IMMUNE-COMPLEX GLOMERULOPATHY IN PATIENTS TREATED WITH CAPTOPRIL , 1980, The Lancet.

[7]  J. Halperin,et al.  Central and Peripheral Hemodynamic Effects of Angiotensin Inhibition in Patients with Refractory Congestive Heart Failure , 1980, Circulation.

[8]  B. Brundage,et al.  Immediate and Sustained Hemodynamic and Clinical Improvement in Chronic Heart Failure by an Oral Angiotensin‐converting Enzyme Inhibitor , 1980, Circulation.

[9]  N. Hollenberg,et al.  Increased glomerular filtration rate after converting-enzyme inhibition in essential hypertension. , 1979, The New England journal of medicine.

[10]  J. Laragh,et al.  Interruption of the Renin‐Angiotensin System in Hypertensive Patients by Captopril Induces Sustained Reduction in Aldosterone Secretion, Potassium Retention and Natriuresis , 1979, Hypertension.

[11]  H. Gavras,et al.  Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. , 1979, Annals of internal medicine.

[12]  T. Ryan,et al.  Angiotensin Converting Enzyme Inhibition in Patients with Congestive Heart Failure , 1978, Circulation.

[13]  J. Cohn,et al.  Role of the Renin-Angiotensin System in the Systemic Vasoconstriction of Chronic Congestive Heart Failure , 1978, Circulation.

[14]  J. Brown,et al.  Renin relationships in congestive cardiac failure, treated and untreated. , 1970, American heart journal.